Cardinal Health closes Syncor deal
Only a few weeks ago, the acquisition of Syncor International by Cardinal Health appeared to be hanging by a thread (SCAN 11/27/02). No more. The deal closed Jan. 1, making Cardinal Health the leading provider of nuclear pharmacy services in the U.S.,
Only a few weeks ago, the acquisition of Syncor International by Cardinal Health appeared to be hanging by a thread (SCAN 11/27/02). No more. The deal closed Jan. 1, making Cardinal Health the leading provider of nuclear pharmacy services in the U.S., according to the company. Syncor's domestic operations will be integrated with Central Pharmacy Services to become the Nuclear Pharmacy Services business of Cardinal Health. Due diligence by Cardinal Health turned up improprieties in certain activities conducted by foreign subsidiaries of Syncor. Subsequent involvement by the U.S. Department of Justice and Securities and Exhange Commission led to a fine and civil penalty. It brought a windfall for Cardinal Health, which adjusted its stock swap purchase price down from $1.1 billion to $750 million.
In the days following the acquisition, Cardinal Health entered a definitive agreement to sell the diagnostic imaging centers previously owned by Syncor to InSight Health Services. Sale of the centers is expected to be finalized through a series of closings beginning about Jan. 31 and running until early May 2003.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
